Valuation: TapImmune Inc

Market Cap 21.93M 19.2M 17.72M 16.55M 31.15M 2.07B 31.86M 213M 82.33M 1.02B 82.34M 80.53M 3.55B P/E 2026 *
-1.37x
P/E 2027 * -1.3x
Enterprise Value 21.93M 19.2M 17.72M 16.55M 31.15M 2.07B 31.86M 213M 82.33M 1.02B 82.34M 80.53M 3.55B EV / Sales 2026 *
7.75x
EV / Sales 2027 * 1.09x
Free-Float
94.51%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 46 2023-04-30
Chief Operating Officer 36 2023-11-30
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 46 2018-10-16
Chairman 65 2022-05-23
Director/Board Member 62 2019-08-05
Change 5-day change 1-year change 3-year change Capi.($)
+4.17%-12.24% - - 21.93M
+0.94%+8.20%-4.77%+1.97% 46.2B
+5.79%+16.17%+423.57%+634.63% 38.71B
+1.12%+15.18%+22.65%-12.71% 31.9B
+3.61%+6.69%+19.80%+62.38% 31.12B
+8.02%+5.23%+17.67%+35.36% 23.77B
+1.13%+15.66% - - 16.2B
+1.45%+17.35%+70.37%+127.60% 15.05B
-1.13%+9.05%+12.03%+18.95% 13.74B
-0.60%+6.32%+104.23%+96.28% 13.42B
Average +2.39%+10.60%+83.19%+120.56% 25.57B
Weighted average by Cap. +2.59%+10.07%+96.10%+142.61%

Financials

2026 *2027 *
Net sales 2.83M 2.48M 2.29M 2.14M 4.02M 268M 4.11M 27.53M 10.63M 132M 10.63M 10.4M 458M 20.09M 17.59M 16.24M 15.16M 28.54M 1.9B 29.19M 195M 75.43M 937M 75.43M 73.77M 3.25B
Net income -19.36M -16.95M -15.65M -14.61M -27.51M -1.83B -28.14M -188M -72.71M -903M -72.71M -71.12M -3.14B -19.89M -17.42M -16.08M -15.01M -28.26M -1.88B -28.91M -193M -74.7M -928M -74.7M -73.06M -3.22B
Net Debt - -
Logo TapImmune Inc
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company’s multi antigen recognizing (MAR)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad-spectrum anti-tumor activity. It is developing two product candidates, including an Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601) and an Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601 to recognize multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-